E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Ischaemia reperfusion injury and allograft pancreatitis. |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation following transplantation |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066127 |
E.1.2 | Term | Ischaemic pancreatitis |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety and anti-inflammatory effect of Tofacitinib on allograft pancreatitis and ischaemia reperfusion, by measuring inflammatory markers in whole blood and assessing CT imaging using an oral dose of Tofacitinib 10mg BD for 7 days
|
|
E.2.2 | Secondary objectives of the trial |
To quantify the level of inflammation observed following reperfusion of organs and identify what inflammatory pathways are being affected.
To assess any association of post-operative complications with administration of the drug. Clinical parameters which affect patient experience and morbidity will also be measured |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Participant is willing and able to give informed consent for participation in the trial. • Male or Female, aged 18 years to 65 years. • Participant is deemed surgically fit to proceed with combined solid organ pancreas kidney transplant • In the Investigator’s opinion, is able and willing to comply with all trial requirements. • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial.
• Willing to undertake effective contraception for the duration of the trial.
|
|
E.4 | Principal exclusion criteria |
• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial. • Bladder drained pancreas transplants will be excluded • Participant with life expectancy of less than 6 months • Patients with Hepatitis B/C and HIV will be excluded • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial. • Known allergy to Tofacitinib • Does not speaks or understands English • Use of contraindicated medication to Tofacitinib as per the appendix of inhibitors and inducers
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Whole blood will be tested for the inflammatory marker C- reactive protein (CRP). CRP has been shown to be a positive surrogate marker for allograft pancreatitis and is the sole primary outcome for the study
CT scan imaging - Timepoint: Day 5 post operatively, will be analysed to measure the amount of inflammation of the pancreas.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients will have 14 blood samples taken at regular intervals following reperfusion of the pancreas.
5ml (one teaspoon) blood samples will be taken during reperfusion of the organ at times 0, 0.5, 1, 2, 4, 6, 12 and 24 hours, then once daily for the first 7 days post-surgery. |
|
E.5.2 | Secondary end point(s) |
To quantify the level of inflammation observed following reperfusion of organs and identify what inflammatory pathways are being affected.
To assess the association of post operative complications and administration of the drug.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Whole blood samples taken during reperfusion of the organ at 0, 0.5, 1, 2, 4, 6, 12 and 24 hours, then once daily for the first 7 days post-surgery, will be additionally tested for full cytokine analysis and cell free circulating DNA.
Patients following transplantation will have all imaging within the first 7 days post-surgery examined to assess the level of allograft inflammation.
Length of hospital stay, number and type of further surgery needed, results of oral glucose tolerance testing and 30 day graft survival will also be measured.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description |
To assess the suitability of tofacitinib in allograft pancreatitis and ischaemia reperfusion. |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 1 |